One of many questions for the conference call.
The company was closing in on the first ever human efficacy for this type of treatment which was always promoted as huge value adder and primer for partnering deals. How was this factored into today's decision?
- Forums
- ASX - By Stock
- Ann: UPDATE ON HCV CLINICAL TRIAL
One of many questions for the conference call. The company was...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm